Literature DB >> 9124863

In vivo oral efficacy of levofloxacin for treatment of systemic Pseudomonas aeruginosa infections in a murine model of septicemia.

S K Yagel1, J F Barrett, D J Amaratunga, M B Frosco.   

Abstract

The in vivo efficacies of levofloxacin and ciprofloxacin in lethal, systemic Pseudomonas aeruginosa infections in mice were compared. MICs of levofloxacin and ciprofloxacin ranged from 0.5 to 2.0 micrograms/ml and from 0.12 to 1.0 microgram/ml respectively. Infecting doses ranged from 5.0 x 10(1) to 3.2 x 10(3) CFU per mouse, depending on the isolate. Test fluoroquinolones were administered orally at 1 h (single dose) or at 1 and 3 h (divided dose) postinfection, with 10 infected mice used for each of six concentrations of each fluoroquinolone tested (1 to 40 mg/kg of body weight) in each dosing regimen. Whether given in a single or a divided dose, the total daily dose was the same for each fluoroquinolone. For mice treated 1 h postinfection with levofloxacin and ciprofloxacin, the effective doses for 50% of the infected mice ranged from 2.09 to 13.80 mg/kg and from 2.34 to 11.22 mg/kg, respectively, and for those treated 1 and 3 h postinfection, the effective doses for 50% of the infected mice ranged from 3.71 to 16.98 mg/kg and from 2.95 to 13.18 mg/kg, respectively. Although the potency varied for both levofloxacin and ciprofloxacin among all strains of P. aeruginosa tested, there were small differences within the same strain for levofloxacin and ciprofloxacin when given in the same dosing regimen. Levofloxacin proved nearly as effective as ciprofloxacin against a systemic P. aeruginosa infection in mice.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9124863      PMCID: PMC163644     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  In vitro and in vivo antibacterial activities of E-4497, a new 3-amine-3-methyl-azetidinyl tricyclic fluoroquinolone.

Authors:  D Gargallo-Viola; M Esteve; S Llovera; X Roca; J Guinea
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  New quinolones--in vivo antibacterial activity.

Authors:  S Goto; S Miyazaki
Journal:  Prog Drug Res       Date:  1992

3.  Quinolone resistance: a practical perspective.

Authors:  C A Wood
Journal:  Arch Intern Med       Date:  1993-01-11

4.  Chemotherapeutic activity of levofloxacin (HR 355, DR-3355) against systemic and localized infections in laboratory animals.

Authors:  N Klesel; K H Geweniger; P Koletzki; D Isert; M Limbert; A Markus; G Riess; H Schramm; P Iyer
Journal:  J Antimicrob Chemother       Date:  1995-06       Impact factor: 5.790

5.  Combination therapy with ciprofloxacin plus azlocillin against Pseudomonas aeruginosa: effect of simultaneous versus staggered administration in an in vitro model of infection.

Authors:  M N Dudley; J Blaser; D Gilbert; K H Mayer; S H Zinner
Journal:  J Infect Dis       Date:  1991-09       Impact factor: 5.226

6.  Pacidamycins, a novel series of antibiotics with anti-Pseudomonas aeruginosa activity. III. Microbiologic profile.

Authors:  P B Fernandes; R N Swanson; D J Hardy; C W Hanson; L Coen; R R Rasmussen; R H Chen
Journal:  J Antibiot (Tokyo)       Date:  1989-04       Impact factor: 2.649

7.  Pseudomonas aeruginosa in a neonatal intensive care unit: reservoirs and ecology of the nosocomial pathogen.

Authors:  H Grundmann; A Kropec; D Hartung; R Berner; F Daschner
Journal:  J Infect Dis       Date:  1993-10       Impact factor: 5.226

8.  In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin.

Authors:  K P Fu; S C Lafredo; B Foleno; D M Isaacson; J F Barrett; A J Tobia; M E Rosenthale
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

Review 9.  The fluoroquinolones.

Authors:  R C Walker; A J Wright
Journal:  Mayo Clin Proc       Date:  1991-12       Impact factor: 7.616

10.  Mortality rates amongst mice with endogenous septicaemia caused by Pseudomonas aeruginosa isolates from various clinical sources.

Authors:  N Furuya; Y Hirakata; K Tomono; T Matsumoto; K Tateda; M Kaku; K Yamaguchi
Journal:  J Med Microbiol       Date:  1993-08       Impact factor: 3.196

View more
  4 in total

1.  Therapy of experimental pseudomonas infections with a nonreplicating genetically modified phage.

Authors:  Steven Hagens; André Habel; Uwe von Ahsen; Alexander von Gabain; Udo Bläsi
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

2.  Italian survey on comparative levofloxacin susceptibility in 334 clinical isolates of Pseudomonas aeruginosa.

Authors:  B Segatore; D Setacci; M Perilli; N Franceschini; A De Santis; F Marchetti; G Amicosante
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

3.  New Mouse Model for Chronic Infections by Gram-Negative Bacteria Enabling the Study of Anti-Infective Efficacy and Host-Microbe Interactions.

Authors:  Daniel Pletzer; Sarah C Mansour; Kelli Wuerth; Negin Rahanjam; Robert E W Hancock
Journal:  mBio       Date:  2017-02-28       Impact factor: 7.867

4.  Micelles self-assembled by 3-O-β-D-glucopyranosyl latycodigenin enhance cell membrane permeability, promote antibiotic pulmonary targeting and improve anti-infective efficacy.

Authors:  Man Zhang; Lili Ye; Hao Huang; Dandan Cheng; Kaixin Liu; Wenbo Wu; Fukui Shen; Zhihong Jiang; Yuanyuan Hou; Gang Bai
Journal:  J Nanobiotechnology       Date:  2020-10-02       Impact factor: 10.435

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.